The global bioabsorbable stents market size was valued at USD 1.14 billion in 2025 and is projected to grow from USD 1.24 billion in 2026 to USD 2.43 billion by 2034, registering a CAGR of 8.76% during the forecast period from 2026 to 2034. North America dominated the bioabsorbable stents market with a market share of 39.8% in 2025.
Bioabsorbable Stents are medical devices designed to temporarily support blocked or narrowed blood vessels and gradually dissolve or get absorbed by the body over time. They are mainly used in cardiovascular procedures to restore blood flow without leaving a permanent implant. The market is driven by the growing prevalence of cardiovascular diseases, increasing demand for minimally invasive procedures, and advancements in biodegradable medical technologies.
Download a Free Sample To learn more about this report,
Multistage Degradation Designs for Controlled Vascular Support
The need to maintain mechanical support during early vascular healing while avoiding long-term material persistence is shifting bioabsorbable stents toward multistage degradation designs, where different layers or materials degrade sequentially to match support requirements with vessel healing; for example, an Fe-based scaffold with a zinc buffer layer can preserve the iron backbone during the first 3 months and subsequently accelerate iron degradation, with near-complete corrosion reported at around 2 years in experimental settings.
Controlled and Remotely Tunable Stent Degradation
The limitations of passive degradation are creating interest in controlled and remotely tunable stent degradation, allowing the degradation rate to be adjusted rather than being determined only by material composition and the physiological environment; recent research has demonstrated a bio-galvanic Fe–Mn–C and platinum system that can actively accelerate metallic dissolution through electrochemical regulation.
Rising Burden of Coronary Artery Disease and Increasing Preference for Temporary Vascular Scaffolding Drive Market
The growing burden of coronary artery disease increases demand for percutaneous coronary interventions and supporting stent technologies, as higher numbers of patients with narrowed or blocked coronary arteries create a broader clinical need for devices that restore blood flow. For example, bioabsorbable stents can provide temporary vessel support after coronary artery lesions are treated through PCI. Rising procedure volumes therefore increase demand for bioabsorbable stents and encourage manufacturers to expand product development and supply.
Greater clinical interest in temporary vascular support increases demand for stents that provide vessel scaffolding without leaving a permanent metallic structure, as the need for temporary support during vessel healing encourages the use of bioabsorbable materials in selected coronary interventions. For example, a bioabsorbable scaffold can support a treated coronary artery while the vessel undergoes healing before the material gradually breaks down. This preference expands the potential use of bioabsorbable stents and encourages suppliers to develop clinically suitable scaffold materials and designs.
Risk of Scaffold Fracture and Mechanical Failure and Concerns Over Revascularization and Clinical Outcomes Restrain Market Expansion
Mechanical limitations such as scaffold fracture, recoil, and insufficient radial strength can affect the structural performance of bioabsorbable stents during and after implantation. These issues can compromise vessel support and increase concerns about procedural and post-treatment outcomes. Such performance risks can reduce physician confidence and slow adoption compared with established metallic stents.
Concerns over restenosis, target-lesion revascularization, and other clinical outcomes can influence physician decisions when selecting bioabsorbable stents. Uncertainty around long-term vessel healing and outcomes can lead clinicians to favor established drug-eluting stents with longer clinical experience. This cautious adoption can limit the use of bioabsorbable stents and constrain market growth.
Expansion into Peripheral Artery Applications and Development of Drug-Eluting Bioabsorbable Stents Offer Growth Opportunities
Peripheral vascular device manufacturers and interventional specialists can target bioabsorbable stents for peripheral artery interventions, extending applications beyond coronary procedures. Companies such as Abbott Laboratories and Biotronik can expand revenue through new vascular-device applications and specialized product portfolios.
Stent manufacturers and pharmaceutical-device developers can combine temporary scaffolding with localized drug delivery for vascular interventions. Companies such as Abbott Laboratories and Boston Scientific can pursue higher-value products through drug-device combinations and differentiated stent technologies.
Limited Anatomical Applicability of Current Bioresorbable Scaffolds and Strong Clinical Preference for Established Drug-Eluting Stents Hinders Growth
Current scaffold designs have restrictions on vessel diameter, lesion length, and lesion complexity, limiting their use across the broader coronary intervention population. For example, the FDA-approved Absorb GT1 was indicated only for vessels 2.5–3.75 mm and lesions up to 24 mm, narrowing its addressable patient population.
Established metallic drug-eluting stents retain a broad evidence base and established clinical workflows, making conversion to bioresorbable technologies difficult. In pooled five-year data from 5,988 patients, Absorb BVS showed higher target-lesion failure than cobalt-chromium everolimus-eluting stents, which can make physicians and hospitals cautious about switching technologies.
The coronary stents segment accounted for a share of 72.5% in 2025 due to the extensive use of stents in treating coronary artery disease and restoring blood flow in narrowed or blocked coronary arteries. The established clinical use of coronary interventions and the growing burden of coronary artery disease support the segment's leading position in the bioabsorbable stents market. The peripheral stents segment is supported by the increasing use of stenting procedures to restore blood flow in peripheral arteries affected by narrowing or blockage. Growing demand for minimally invasive vascular interventions and the development of bioabsorbable technologies for peripheral applications are supporting segment adoption.
The polymer-based stents segment benefits from the ability of biodegradable polymers to gradually degrade after serving their intended function, potentially reducing the need for a permanent implant. Their tunable degradation characteristics and ongoing development for controlled drug delivery support their use in bioabsorbable stent applications. The metal-based stents segment is supported by the mechanical strength and structural stability provided by biodegradable metals in vascular applications. Their ability to provide temporary vessel support while gradually degrading is driving research and adoption of metal-based bioabsorbable stent technologies.
Request Customizationto receive a tailored report.
The polymer-based stents segment accounted for a share of 64.7% in 2025 due to the widespread use of biodegradable polymers in bioabsorbable stents, where they provide temporary vessel support and gradually degrade after fulfilling their therapeutic function. Their tunable degradation properties and compatibility with controlled drug delivery support their use in coronary and other vascular interventions. Growing research and development of polymer-based bioabsorbable stents further supports the segment's leading market position.
The metal-based stents segment is expected to grow at a CAGR of 7.96%, driven by increasing demand for bioabsorbable metallic materials that provide higher mechanical strength and structural support during vascular healing. Biodegradable metals can maintain vessel support while gradually degrading, making them suitable for applications requiring temporary scaffolding. Ongoing development of metal-based bioabsorbable stent technologies is supporting their adoption in vascular interventions.
The slow-absorption stents segment accounted for a share of 69.2% in 2025 due to their ability to provide prolonged vascular support while the treated vessel undergoes healing and remodeling. Their gradual degradation helps maintain mechanical support over a longer period, supporting their use in coronary and other vascular interventions. The established use of slow-degrading materials in bioabsorbable stent designs further supports the segment's leading market position.
The fast-absorption stents segment is expected to grow at a CAGR of 8.28%, driven by increasing demand for stents that provide temporary vascular support while degrading more rapidly after treatment. Faster absorption can reduce the duration of foreign-material exposure within the vessel, supporting interest in next-generation bioabsorbable stent designs. Ongoing development of materials with controlled and predictable absorption rates is further supporting adoption of fast-absorption stents.
The hospitals segment accounted for a share of 57.8% in 2025 due to the high volume of cardiovascular procedures performed in hospital settings, including coronary interventions requiring stent placement. The availability of specialized cardiac units, advanced medical infrastructure, and trained healthcare professionals supports the use of bioabsorbable stents in hospitals. Their role as major centers for complex cardiovascular care further strengthens the segment's market position.
The ambulatory surgical centers segment is expected to grow at a CAGR of 9.42%, driven by the increasing shift toward minimally invasive cardiovascular procedures in outpatient settings. Growing demand for shorter hospital stays, lower procedural costs, and efficient post-procedure recovery is supporting the adoption of advanced stenting technologies in these centers. The expansion of cardiovascular procedures suitable for same-day care further supports segment growth. The cardiac centers segment is supported by the increasing volume of specialized cardiovascular procedures and the growing need for dedicated facilities for coronary interventions. Access to specialized cardiac equipment, interventional cardiologists, and focused cardiovascular care supports the use of bioabsorbable stents in these facilities.
Speak to an Analystto discuss market opportunities.
The North America bioabsorbable stents market accounted for the largest regional share of 39.8% in 2025, supported by advanced cardiovascular healthcare infrastructure, increasing adoption of minimally invasive procedures, and continued investment in interventional cardiology technologies. Growing demand for stent technologies that can provide temporary vascular support while gradually being absorbed by the body is also supporting market development across the region.
The United States bioabsorbable stents market is expected to benefit from the rising cardiovascular disease burden, with the American Heart Association projecting the prevalence of coronary heart disease to increase from 7.5% in 2025 to 8.2% by 2035, supporting demand for coronary intervention technologies.
The Canada bioabsorbable stents market is expected to benefit from population aging, with Statistics Canada projecting the share of people aged 65 and older to rise from 19.5% in 2025 to 22.6%–32.5% by 2075, while the population aged 85 and older is projected to increase from 951,833 to 3.3–4.2 million, supporting demand for cardiovascular care and minimally invasive interventions.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific bioabsorbable stents market is expected to grow at a CAGR of 10.48% during the forecast period, making it the fastest-growing regional market, supported by the region’s growing cardiovascular disease burden, with WHO reporting that cardiovascular diseases caused more than 4.25 million deaths in Southeast Asia in 2021 and setting a 2030 target to reduce premature CVD mortality by 33.3%, which is expected to strengthen demand for cardiovascular interventions and treatment technologies.
The China bioabsorbable stents market is expected to benefit from continued cardiovascular disease management, with China’s National Health Commission targeting a cardiovascular disease mortality rate below 190.7 per 100,000 people by 2030 and a nationwide system for cardiovascular disease prevention, early detection, and treatment, supporting demand for advanced coronary interventions. The Japan bioabsorbable stents market is expected to benefit from population aging, with Japan’s official population projections indicating that people aged 65 and older will account for about 38.7% of the population by 2070, increasing the need for cardiovascular disease management and minimally invasive interventions.
The South Korea bioabsorbable stents market is expected to benefit from the growing cardiovascular disease burden associated with population aging, with projections indicating that cardiovascular and circulatory diseases could account for about 83,348 deaths in 2030, compared with approximately 76,000 in 2015, supporting demand for coronary interventions. The India bioabsorbable stents market is expected to benefit from the projected cardiovascular disease burden, with WHO projections indicating more than 4.68 million cardiovascular disease deaths in South Asia in 2030, including about 2.27 million deaths from ischemic heart disease, supporting continued demand for cardiovascular treatment technologies.
The Europe bioabsorbable stents market accounted for a market share of 28.4% in 2025, supported by the region’s established cardiovascular care infrastructure and high burden of cardiovascular disease. The European Commission projects the number of people living with cardiovascular disease in Europe to increase from around 62 million currently to more than 100 million by 2050 due to population aging, supporting long-term demand for cardiovascular interventions and minimally invasive treatment technologies.
The U.K. bioabsorbable stents market is expected to benefit from an aging population and rising cardiovascular-care needs, with England’s population aged 65–84 projected to increase by 29% and those aged 85 and over by 61% by 2030, supporting demand for coronary interventions and other cardiovascular treatments. The Germany bioabsorbable stents market is expected to benefit from population aging, with Germany’s Federal Statistical Office projecting that one in four people will be aged 67 or older by 2035, while the 67+ population is projected to reach 20.5–21.3 million by 2038, supporting demand for cardiovascular interventions. The France bioabsorbable stents market is expected to benefit from continued population aging, with INSEE’s 2026 projections extending to 2070 and indicating that France will have an older population than in 2026, increasing the potential need for cardiovascular disease management and minimally invasive interventions.
The bioabsorbable stents market is moderately fragmented, with participation from established medical device manufacturers, cardiovascular technology companies, specialized stent developers, and smaller firms focused on advanced biomaterials and drug-delivery technologies. Abbott, Boston Scientific Corporation, Biotronik SE & Co. KG, Elixir Medical Corporation, and Medtronic plc are the leading players in the bioabsorbable stents market; however, a reliable cumulative market-share figure for these five companies is not publicly disclosed by credible primary or independent non-market-research sources, so a specific percentage would be unsupported.
Established players compete primarily on clinical evidence, stent design, bioabsorption performance, drug-delivery capabilities, and relationships with hospitals and interventional cardiologists. Emerging players in the bioabsorbable stents market ecosystem compete through novel biodegradable materials, thinner stent platforms, improved mechanical performance, and application-specific designs, while seeking to address limitations associated with conventional and earlier-generation bioabsorbable stent technologies.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Respiratory Disposables Market Size, Share, Growth, Analysis, 2034
Manual Resuscitators Market Size, Share, Growth, Analysis, 2034
Europe Plasmapheresis Machine Market Size, Share & Growth by 2034
Cardiac Resynchronization Therapy (CRT) Market Size, Share, 2034
Asia Pacific Plasmapheresis Machines Market Size, Share and Forecast to 2034
Latin America Cardiac Resynchronization Therapy (CRT) Market Size, Share and Forecast to 2034
We are featured on:
sales@straitsresearch.com